REVLIMID 10 MG CAPSULAS DURAS

EUEMA:by INNUSDailyMed:Lenalidomide AU:X (High risk) L04AX04(WHO) AU:S4(Prescription only)BR:Class C3(Immunosuppressive drugs)UK:POM(Prescription only)US:℞-onlyEU:Rx-only (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 191732-72-6Y 216326 7331 DB00480Y 187515Y F0P408N6V4 D04687Y ChEMBL848Y DTXSID8046664 Interactive image O=C1NC(=O)CCC1N3C(=O)c2cccc(c2C3)N InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)YKey:GOTYRUGSSMKFNF-UHFFFAOYSA-NY Lenalidomide, sold under the brand nameRevlimidamong ​​​‍​​‍​​​​‍​​‍‍others, is a medication used to treatmultiple myeloma,smoldering myeloma, variousindolent lymphomas, andmyelodysplastic syndromes(MDS).For multiple myeloma, it is a first-line treatment, and is given withdexamethasone.It is takenby mouth. Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping.Severe side effects includelow blood platelets,low white blood cells, andblood clots.The dose may need to be adjusted in people withkidney problems.Lenalidomide is closely related tothalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus. Lenalidomide belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs) orCereblon E3 ligase modulators, which includesthalidomideand its analogs.Inlymphocytes, these drugs target anE3 ubiquitin ligaseand change its specificity to include new targets.This results in the rapid degradation of several disease-related proteins includingIKZF1,IKZF3, andCSNK1A1. Lenalidomide was approved for medical use in the United States in 2005.It is on theWorld Health Organization's List of Essential Medicines.